Skip to content
  • About us
    • Overview
    • Our founders
    • Careers
  • Our pipeline
    • Development pipeline
    • Netazepide
      • Background
      • Studies
      • Further studies
    • Ceclazepide
    • TR4
    • TR8
  • Trio Medicines Logo
  • Our publications
  • Contact us
Next

The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.

Kidd M, Siddique Z, Drozdov I, Gustafsson B, Camp R, Black JW, Boyce M, Modlin I. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL-cell hyperplasia and gastric carcinoid tumor development.  Regul Pept 2010; 162: 52–60.

training2019-03-26T13:22:08+00:00

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditGoogle+TumblrPinterestVkEmail